Relday is a proprietary, once-monthly subcutaneous investigational formulation of risperidone for treating schizophrenia.

There are currently over 2.4 million patients diagnosed with schizophrenia in the United States.  Due to treatment compliance challenges, the paradigm for treatment is evolving towards earlier use of long-acting injections (LAIs).

Relday's unique product profile was designed to overcome complexities associated with current long-acting injectable treatments for schizophrenia:

  • No oral supplementation / complicated loading dose regimens 
  • Initiation dose identical to maintenance dose 
  • Once-monthly dosing interval 
  • Subcutaneous administration 
  • No need for reconstitution prior to use 



Relday is a registered trademark of Zogenix, Inc.